Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05866679 | Recruiting | Ovarian Cancer

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
Sponsor:

M.D. Anderson Cancer Center

Brief Summary:

To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.

Condition or disease

Ovarian Cancer

Intervention/treatment

Hyperpolarized 13-C-pyruvate

Phase

Phase 1

Detailed Description:

Primary Objective: To assess if increased lactate production measured by HP 13C MRI occurs in suspected ovarian cancer patients who will undergo surgery To evaluate the proportion of increased lactate production in the ovaries measured by HP 13C MRI in low/high ovarian cancer risk patients. Secondary Objectives: Correlate HP-MR findings to metabolomics, immune profiles, and blood biomarkers of patients undergoing surgical resection. Demonstrate the feasibility and utility of metabolic imaging with HP 13C pyruvate MR in patients with suspected ovarian cancer Correlating imaging findings such as enhancement pattern, ADC values, and advanced image analytics such as texture with pathology and genetic analysis for patients who will undergo surgical resection.}}

Study Type : Interventional
Estimated Enrollment : 30 participants
Masking : None (Open Label)
Primary Purpose : Diagnostic
Official Title : Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
Actual Study Start Date : April 12, 2024
Estimated Primary Completion Date : August 31, 2026
Estimated Study Completion Date : August 31, 2028
Arm Intervention/treatment

Experimental: Hyperpolarized 13-C-pyruvate

Drug: Hyperpolarized 13-C-pyruvate
Ages Eligible for Study: 18 Months
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • For the first cohort, the following selection criteria will be applied who are undergoing a screening exam at MD Anderson
    • Patients with a first degree relative (mother, sister, or daughter) with ovarian cancer or
    • A personal history of breast cancer before age 40 or
    • A personal history of breast cancer diagnosed before age 50, and one or more close relatives diagnosed with breast or ovarian cancer at any age. Two or more close relatives diagnosed with breast cancer before age 50 or with ovarian cancer diagnosed at any age or
    • Ashkenazi Jewish heritage and a personal history of breast cancer before age 50 or
    • Ashkenazi Jewish heritage and a first- or second-degree relative diagnosed with breast cancer before age 50 or with ovarian cancer at any age or
    • Presence of a BRCA1 or BRCA2 mutation or
    • Presence of a mismatch repair gene mutation associated with a hereditary cancer syndrome known as Hereditary Non-Polyposis Colon Cancer (HNPCC)/Lynch syndrome. For the second cohort- 10 Patients will be enrolled who present to MD Anderson for a pelvic ultrasound or have an outside ultrasound or imaging study without a mass or have an adnexal mass (benign) on outside imaging and do not have a high risk for ovarian cancer.
    • For the third cohort of patients
      • 10 patients who have suspicion of ovarian malignancy on conventional imaging and will be undergoing surgical resection will be included.
      Exclusion Criteria
      • (all cohorts)
      • 1. Children, pregnant women, cognitively impaired adults, or prisoners will be excluded from participation.
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Location Details

Please Choose a site

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Recruiting

United States, Texas

M D Anderson Cancer Center

Houston, Texas, United States, 77030